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amount of 340 000 € could have been saved. CONCLUSIONS: Adherence to princi-
ples of good antibiotic policies leads to fundamental short and long term financial
savings within the budget of a health insurance fund.
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OBJECTIVES: Clostridium difficile infection (CDI) can lead to several complications
from mild diarrhoea to toxic megacolon. The objectives of this study were to: 1)
evaluate standard Time trade-off (TTO) and chain TTO techniques for eliciting
utility of CDI-related chronic and temporary health states; 2) compare those values
with those from Healthcare Professional (HCP) EQ-5D valuation; 3) evaluate meth-
ods of calculating utilities for health states worse than death (WTD). METHODS:
Ten health state vignettes were developed from literature with input from HCPs.
Participants from the UK public were interviewed: 50 for the pilot and 100 for the
main study. Each participant provided sociodemographic information, ranking of
health states by preference and responses to a Computer-Assisted Personal Inter-
view TTO protocol for all states considered. HCPs provided EQ-5D data. Methods to
apprehend the impact of extreme negative utilities were appraised: truncation and
monotonic transformation.RESULTS:Temporary health state utilities ranged from
(mean and (/) median from non transformed method; mean and median (/) from
monotonically transformed method): -2.70/0.7;0.39/0.6 for mild diarrhoea to
-32.50/-1.1; -0.23/-0.5 for colectomy. Chronic health state ranged from: -2.37/0.5;
0.35/0.5 for chronic diarrhoea to -7.98/0;-0.13/0 for chronic renal failure. Population
valuations were more severe for most health states when compared with HCP
values. CONCLUSIONS: While transformation has an important impact on results,
nowadays there is no reliable measure of utilities for CDI-health states. The pro-
portion of participants judging health states as WTD was unexpectedly high; ques-
tioning the suitability of face-to-face TTO interview in this disease area. The mono-
tonic transformation was convenient but lacks theoretical grounding. Other
methods like Lead Time trade-off could add value to similar research.
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OBJECTIVES: To investigate health related quality of life (HRQOL) in non-engaging
HIV infected intravenous drug users (IVDUs) over a one year time period.
METHODS: This was a prospective observational cohort study of non-engaging
adult HIV infected IVDUs registered for care at an inner city HIV unit (non-engage-
ment defined as missing  2 HIV outpatient appointments over one year or not
attending outpatients for six months). EQ-5D, SF-36, Hospital Anxiety Depression
scale (HADs), clinical and substance misuse data were collected on a six monthly
basis. Regression models were fitted to identify the statistical relationship between
utility and HADs. The relationship between measures was assessed using spear-
man’s correlation for non-parametric data. RESULTS: Fifty-two patients were in-
cluded (125 observations). Sixty two percent were male with a mean age of 37 yrs.
The mean anxiety value was 10.9 (borderline anxiety), and mean Depression score
was 9.3 (borderline depressed). The mean EQ5D utility score was 0.51(95% CI: 0.45 –
0.59) Fifteen patients (12%) had an EQ5D utility worse than death of whom 14 (93%)
were anxious and 13 (86%) were depressed. The mean SF6D utility was 0.53 (95%CI:
0.51 – 0.55). Mean Physical component score (PCS) was 53.91, and mental compo-
nent score (MCS) was 34.03. Role physical had the lowest mean score at 28.07, and
was significantly correlated with anxiety (spearman’s correlation -0.318, signifi-
cant at 0.01 level, 2 tailed), depression (spearmans’s correlation -0.316, significant
at 0.01 level, 2 tailed), virological suppression (spearman’s correlation -0.194 sig-
nificant at 0.05 level, 2 tailed) and HIV viral load (spearman’s correlation -0.207,
significant at 0.05 level, 2 tailed). CONCLUSIONS: HRQOL was severely reduced in
this non-engaging HIV infected IVDU population. Whilst HCV co-infection and
substance misuse did not affect the HRQOL, anxiety and depression had a signifi-
cant impact upon it.
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OBJECTIVES: Cytomegalovirus (CMV) is responsible directly or indirectly for an
increase of mortality and morbidity in patients with solid organ transplantation
(SOT) and hematopoietic stem cell transplantation (HSCT). Our aim was to identify
HRQoL dimensions affected by CMV infections and management after HSCT or
SOT. METHODS: A literature review on transplanted patients’ HRQoL through the
EMBASE database was performed. We also looked for issues raised by patients in
specialized forums. Individual interviews were conducted with 4 clinical experts
and 20 patients, divided equally into HSCT and SOT groups. Clinical practitioners
were asked to identify key concepts attributable to the CMV-disease (symptoms) or
antiviral side effects versus transplantation-related. Patients were asked to cite
important concepts and rate them. All patient responses were coded. Code fre-
quency and bother ratings were used to identify salient patient experiences.
RESULTS: Preliminary analysis suggests that it is difficult to isolate the effects of
the CMV infection and the antiviral treatment due to other untolerated medica-
tions (e.g. immunosuppressive drugs) and/or the patient’s underlying medical con-
dition. Key reported symptoms include fever and (worsened) tiredness. Tiredness
was often described as being related to physical activity limitation. Key areas im-
pacted by CMV infection and CMV treatment included physical activity and mobil-
ity limitations, as well as mental fatigue and stress. Practitioner judgments helped
classify the different concepts into one of 3 categories, CMV-disease symptom,
treatment side effects, and psychological concerns. CONCLUSIONS: The CMV im-
pact was found to be quite heterogeneous between patients as it seems to be
dependent on type of transplantation, experience of symptomatic infection and
tolerance of antidepressants. This qualitative study suggested that physical activ-
ity, mobility, mental fatigue, and stress are key QoL dimensions affected by CMV
management, infections and treatments in transplanted patients.
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Primary immunodeficiency (PI) constitutes a group of disorders involving a primary
defect in the immune system often requiring lifelong Immunoglobulin (IG) therapy
which can be administered intravenously (IGIV) or subcutaneously (IGSC).
OBJECTIVES: To quantify patient and caregivers preferences for administration
attributes of IG treatments. METHODS: Adult patients and caregivers of children
with PI from 21 non-U.S. countries recruited via national member organisations
completed a web-enabled, choice-format survey. The conjoint analysis quantified
the preferences of attributes presented to the respondents. The preference weights
for each sample were scaled between 0 and 10. The vertical distance between
adjacent preference weights indicated the relative importance of moving from one
level of an attribute to an adjacent level of that attribute. RESULTS: A total of 216
patients and 84 caregivers completed the survey. Patients and caregivers signifi-
cantly preferred monthly to weekly, home setting to doctor’s office/hospital/ clinic,
shorter duration, and fewer needle sticks of IG treatment (P  0.05). There was a
difference in the ranking of these attributes between IGIV and IGSC users. IGIV
users indicated frequency as the most important attribute followed by number of
needle sticks, duration and home setting while IGSC users indicated home setting
as the most important attribute followed by duration, self administration, number
of needle sticks, and frequency. CONCLUSIONS: IG treatments that provide the
comprehensive option of a monthly frequency, home setting, shorter duration, and
fewer needle sticks may address the needs of both PI patients and caregivers,
although ranking of these attributes may be different between the IGIV and IGSC
users.
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OBJECTIVES: Hepatitis C virus (HCV) infection may cause cognitive impairment,
but no studies have focused specifically on cognitive impairment stemming from
Alzheimer’s disease. The purpose of this study was to investigate the potential
increased risk for Alzheimer’s disease in HCV-infected patients. METHODS: We
conducted a population-based cohort study from the Taiwan National Health In-
surance Research Database. From all potential participants aged fifty years or
more, a total of 117,098 matched (1:1) pairs of HCV-infected patients and non-HCV-
infected patients were included. Each subject was individually tracked from 1997 to
2009 to identify incident cases of Alzheimer’s disease (onset in 1999 or later). Cox
proportional hazard regressions were employed to calculate the hazard ratios (HRs)
and 95% confidence intervals (CIs) for the association between HCV infection and
Alzheimer’s disease in the HCV-infected cohort. RESULTS: There were 830 cases of
Alzheimer’s disease reported in the HCV cohort during follow-up periods of
1,122,436.9 person-years, with incidence rates of 73.9 cases per 100,000 person-
years (95% CI, 69.1-79.2). The multivariate-adjusted HR for Alzheimer’s disease was
1.14 (95% CI, 1.02-1.26) for HCV-infected patients. The HR for HCV-infected patients
in their sixties (1.18, p  0.05) was higher than for other subgroups. There were
5,243 HCV-infected patients (4.48%) who completed antivirus therapy. The HR of
treated patients was 0.31 (95% CI 0.15-0.67) after adjusting for age, gender, income,
urbanization and the presence of other medical diseases. CONCLUSIONS: HCV
infection may increase the risk for Alzheimer’s disease. HCV antiviral therapy
could lower the risk of AD in HCV-infected patients.
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OBJECTIVES: To explore the major determinants associated with treatment switch
in CHB treated patients from a cohort across 5 EU countries. METHODS: Multivar-
iate Cox proportional hazard regression model was used to analyze determinants
of treatment switch by a backward selection. Data analyzed were derived from an
observational cohort study, consisting of diagnosed adult CHB patients managed in
outpatient clinics, prospectively enrolled from March-2008 to October-2009, in
France, Germany, Poland, Romania and Turkey. Patients with HIV and/or HCV
co-infection and hepatocellular-carcinoma or liver failure at baseline were ex-
cluded. Factors considered candidates to enter the multivariate model (with uni-
variate test at p-value0.20) were: country, ALT level before switch, VL level before
switch, liver biopsy test performed, Hepatitis B e-antigen status, CHB status, age
and agent received before switch. The statistical criteria for exclusion at each step
of the model building process is p-value0.05. Results are presented as hazard
ratio(HR), [95% confidence interval] and p-value. RESULTS: Data were collected for
1267 patients followed for up to 2 years with a median (months) ranging from 12.5
(Poland) to 14.5 (Romania). A total of 567 patients received a treatment at baseline
and were included in the model to analyze the determinants of treatment switch.
Time on last treatment before switch was 1.9 years (median). There is a higher
probability to treatment switch in France (5.19;[1.76-15.24];p.0027), Germany
(4.80;[1.60-14.39];p.0050), and Poland (4.42;[1.41-13.83];p.0106) compared to Tur-
key. No statistically difference in Romania. There is a higher probability to treat-
ment switch when VL2000IU/ml (4.35;[2.52-7.52];p.0001) compared to Undetect-
able and VL2000IU/ml. Analysis of interaction showed that VL when associated
with a performed liver biopsy test increase probability of switch. CONCLUSIONS:
This observational cohort identified VL level as a major clinical outcome driving the
treatment switch decision in CHB treated patients. Results were statistically differ-
ent across countries, possibly due to different health care policies.
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OBJECTIVES: To explore the perceptions’ of hospital pharmacists towards drug
management and reasons underlying stock outs of anti-malarial drugs in Pakistan.
METHODS:A qualitative study was designed to explore the perceptions’ of hospital
pharmacists regarding drug management and irrational use of anti-malarial drugs
in two major cities of Pakistan, namely, Islamabad (national capital) and Rawal-
pindi (twin city). Semi-structured interviews were conducted using in-depth inter-
view guides to collect data. Sixteen interviews with hospital pharmacists working
at different public and private hospitals in Islamabad and Rawalpindi were con-
ducted at a place and time convenient for the respondents. Interviews, were audio-
taped and transcribed verbatim, were evaluated by thematic content analysis and
by other authors’ analysis. RESULTS: The interviews with hospital pharmacists
focused on three major components i.e. drug management, contributing factors in
stock-outs, role of hospital pharmacist and suggestions for improvements. The-
matic content analysis of these components yielded further themes.1,2) Preva-
lence and current scenario of malaria treatment practices 3) Major contributing
factors towards irrational treatment practices for malaria 4,5,6) Role of health care
system and hospital pharmacist and influencing factor effective drug management
and treatment practices 5 7) Collaborative working of doctors and pharmacists 8)
Role of Malaria Control Program 9) Management of anti-malarial drugs in the
health care facilities 9,10,11) Current scenario, contributing factors and strategies
to improve in anti-malarial drugs stock outs. CONCLUSIONS: The current study
showed that all the respondents in the two cities agreed that hospital pharmacist
has failed to play an effective role in efficient management of anti-malarial drugs
stock-outs.
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OBJECTIVES: Cross-country regressions have been used to assess the relationship
between malaria and economic growth. However, more detailed estimates of the
broad economic impact of malaria interventions targeting children i.e. impact at
household level and per region are relevant to donors and policymakers. Therefore,
we simulate the impact of reducing malaria morbidity and mortality on the Gha-
naian economy utilising a micro-based approach. METHODS: A multi-sector,
multi-agent, dynamic-computable-general-equilibrium (DCGE) model is devel-
oped and linked with health models that estimate: (1) regional demographics with
cohort-component projections for fertility, mortality, migration, and urbanization;
(2) labour indices for production and productivity of parents with sick children or
adults affected by malaria during childhood. We leave out any additional effects
(tourism spending, foreign investment, etc.). The model is calibrated to Ghana,
with households disaggregated by five epidemiological malaria regions, urban-
rural divide, and income level quintiles. Hypothetical intervention scenarios are
simulated reducing malaria prevalence by 50%, for children 5years with varying
degrees of coverage. RESULTS: Average yearly GDP would rise by 0.8% above base-
line. Due to regional heterogeneity in labour resources, preferences, and malaria
prevalence, the income-benefit per child covered by the intervention ranges be-
tween $1-$14, $5-$50 and $66-$540 (2007 US Prices) with national averages of $8, $34
and $300 at y1, y15 and y25 respectively. We also find that malaria prevention
contributes more to income and consumption in high prevalence regions, and
slows down the rise in income inequalities under the limitation that the model
does not include the informal sector. CONCLUSIONS: Investing in malaria preven-
tion in children can have an observable impact on the wider economy and may
contribute to poverty reduction. We contribute with: (1) a public economics ap-
proach to analysing malaria impact on economic growth (2) viewing effects at
national, regional, and income level dimension; (3) a suitable method for other
diseases.
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OBJECTIVES: In Europe, the time between regulatory approval and population ac-
cess for vaccines exceeds that for other pharmaceutical products. This difference
has been shown to be linked to the recommendation phase, where NITAGs assess
new vaccines before implementation into vaccination programmes and coverage
by health insurance. The objective of this research was to study and compare
NITAGs’ policies and decision-making processes in 9 European and 4 non-Euro-
pean countries. METHODS: We developed a standardized extraction grid with 25
items covering: overall NITAG organization, existence of terms of reference, mem-
ber’s appointments and profiles, meeting organization, decision analytic frame-
work, processes and communication. The research was conducted by review of the
NITAG or mother agency websites, and a literature review and direct contact with
a NITAG member by email, and when possible by telephone interview. RESULTS:
Information was rarely available online or through public sources. Direct contact
was necessary to obtain information for most countries. Only 2 EU countries (and
the 4 non-EU countries) have formal terms of reference. In most cases defined
missions do not fit to actual ones. Numbers (8 to 48) and backgrounds of experts
varied dramatically. 69% of NITAGs have analytical frameworks, 8% have publicly-
opened meetings, 15% publish meeting agendas, 31% publish minutes and 85%
publish recommendations. The vast majority have no defined timelines for
decision-making. CONCLUSIONS: Wide variability in organization processes and
communication is seen between NITAGs. In Europe, NITAGs with few terms of
references and no communication of meeting agendas or minutes suggests the
lack of a structured and transparent decision-making process. There is an obvious
need for improving the vaccine decision-making process. Some interesting initia-
tives from individual NITAGs could be taken as examples and assembled together
for a benchmark exercise. Recommendations for best practices in vaccine decision
making are critical to public health and will be discussed.
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OBJECTIVES: Systemic antibacterials are frequently used by children. We assessed
trends in prevalence of antibacterial drug use among Dutch children from 2005
until 2010. METHODS: The PHARMO Record Linkage System, containing amongst
others outpatient pharmacy dispensing data of 3.2 million inhabitants in the
Netherlands, was used for this study. For every year in the study period 2005-2010,
the number of children aged 0-18 years with any dispensing of systemic antibac-
terials and per subtype was counted and extrapolated to the Netherlands, stan-
dardized for age and gender. Prevalence of use was reported per 10,000 children
and was stratified by calendar year, age group (2 years: infants and toddlers, 2-11
years: children, 12-18 years: adolescents) and gender. RESULTS: The prevalence of
antibacterial drug use decreased 1.1-fold among infants and toddlers (from 2,231 to
2,041 per 10,000), decreased 1.3-fold among children (from 1,979 to 1,564 per
10,000), but remained constant among adolescents (1,193 per 10,000). A decrease of
use was mainly observed in the most prevalent types; penicillins with extended
spectrum and macrolides. However, also trimethoprim and derivatives were less
frequently used, especially among female adolescents (from 163 to 92 per 10,000).
Prevalence of beta-lactamase resistant penicillins increased from 2 to 29 per 10,000
among infants and toddlers and from 44 to 77 per 10,000 among children. An
increase in nitrofuran derivatives was observed among female children (from 38 to
100 per 10,000) and female adolescents (from 267 to 413 per 10,000).CONCLUSIONS:
This study provides an extensive overview of trends in antibacterial drug use
among children in the Netherlands. An overall decrease of use was observed, while
an increase was observed for nitrofuran derivatives and beta-lactamase resistant
penicillins.
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